PARP（ポリADPリボースポリメラーゼ）阻害剤のグローバル市場2021

• 英文タイトル：Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Report 2021

• レポートコード：QAF27370
• 出版社/出版日：QYResearch / 2021年4月16日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、135ページ
• 納品方法：Eメール（即日納品）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥600,000 (USD4,000)	▷ お問い合わせ
Multi User	￥900,000 (USD6,000)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本市場調査資料では、世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場について種類別（リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他）、用途別（卵巣がん、乳がん、その他）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・PARP（ポリADPリボースポリメラーゼ）阻害剤市場の概要
・世界の主要地域別PARP（ポリADPリボースポリメラーゼ）阻害剤市場規模2016-2027
・主要プレイヤーの競争状況・市場シェア
・世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場規模2016-2021：種類別（リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他）
・世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場予測2012-2027：種類別（リンパルザ、ゼジュラ、ルブラカ、タルゼンナ、その他）
・世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場規模2016-2021：用途別（卵巣がん、乳がん、その他）
・世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場予測2012-2027：用途別（卵巣がん、乳がん、その他）
・PARP（ポリADPリボースポリメラーゼ）阻害剤のアメリカ市場規模と予測2016-2021
・PARP（ポリADPリボースポリメラーゼ）阻害剤のヨーロッパ市場規模と予測2016-2021
・PARP（ポリADPリボースポリメラーゼ）阻害剤の中国市場規模と予測2016-2021
・PARP（ポリADPリボースポリメラーゼ）阻害剤の日本市場規模と予測2016-2021
・PARP（ポリADPリボースポリメラーゼ）阻害剤の東南アジア市場規模と予測2016-2021
・PARP（ポリADPリボースポリメラーゼ）阻害剤のインド市場規模と予測2016-2021
・主要プレイヤーの企業情報：事業概要・売上・企業動向
（AstraZeneca、Tesaro、Merck & Co、Clovis Oncology、Pfizer）
・PARP（ポリADPリボースポリメラーゼ）阻害剤の製造コスト分析
・販売チャネル、流通業者、顧客
・PARP（ポリADPリボースポリメラーゼ）阻害剤の市場動向・機会・課題
・調査の結論

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.

Market Analysis and Insights: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market was valued at US$ 3917.3 in 2020 and will reach US$ 21490 million by the end of 2027, growing at a CAGR of 32.8% during 2022-2027.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Scope and Market Size
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other

Segment by Application
Ovarian Cancer
Breast Cancer
Other

The PARP (Poly ADP-Ribose Polymerase) Inhibitor market is analysed and market size information is provided by regions (countries). Segment by Application, the PARP (Poly ADP-Ribose Polymerase) Inhibitor market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer

レポート目次

1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Scope
1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016 & 2021 & 2027)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Estimates and Forecasts (2016-2027)
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size in Value Growth Rate (2016-2027)
1.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Trends (2016-2027)

2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Forecasts by Region
2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2016-2021)
2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2016-2021)
2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
2.4.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
2.4.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
2.4.4 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
2.4.5 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
2.4.6 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Estimates and Projections (2016-2027)
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Competition Landscape by Players
3.1 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Players by Sales (2016-2021)
3.2 Global Top PARP (Poly ADP-Ribose Polymerase) Inhibitor Players by Revenue (2016-2021)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2020)
3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Company (2016-2021)
3.5 Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Review by Type (2016-2021)
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2016-2021)
4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2016-2021)
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2022-2027)
4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Type (2022-2027)
4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Forecast by Type (2022-2027)
5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Historic Market Review by Application (2016-2021)
5.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
5.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2016-2021)
5.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2016-2021)
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2022-2027)
5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Application (2022-2027)
5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Forecast by Application (2022-2027)

6 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
6.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
6.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
6.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
6.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
6.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
6.2.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
6.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
6.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2016-2021)
6.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2022-2027)

7 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
7.2.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
7.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
7.3.1 Europe 135 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 135 Sales Breakdown by Application (2022-2027)

8 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
8.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
8.1.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
8.1.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
8.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
8.2.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
8.2.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
8.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
8.3.1 China 247 Sales Breakdown by Application (2016-2021)
8.3.2 China 247 Sales Breakdown by Application (2022-2027)

9 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
9.1 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
9.1.1 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
9.1.2 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
9.2 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
9.2.1 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
9.2.2 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
9.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
10.1 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
10.1.1 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
10.1.2 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
10.2 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
10.2.1 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures
11.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company
11.1.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2016-2021)
11.1.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021)
11.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type
11.2.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2016-2021)
11.2.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Type (2022-2027)
11.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application
11.3.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2016-2021)
11.3.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in PARP (Poly ADP-Ribose Polymerase) Inhibitor Business
12.1 AstraZeneca
12.1.1 AstraZeneca Corporation Information
12.1.2 AstraZeneca Business Overview
12.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2016-2021)
12.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
12.1.5 AstraZeneca Recent Development
12.2 Tesaro
12.2.1 Tesaro Corporation Information
12.2.2 Tesaro Business Overview
12.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
12.2.5 Tesaro Recent Development
12.3 Merck & Co
12.3.1 Merck & Co Corporation Information
12.3.2 Merck & Co Business Overview
12.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
12.3.5 Merck & Co Recent Development
12.4 Clovis Oncology
12.4.1 Clovis Oncology Corporation Information
12.4.2 Clovis Oncology Business Overview
12.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
12.4.5 Clovis Oncology Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Business Overview
12.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
12.5.5 Pfizer Recent Development
…

13 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Cost Analysis
13.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
13.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
14.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers

15 Market Dynamics
15.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
15.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Drivers
15.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
15.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Region (2016-2021)
Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2016-2021)
Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Region (2016-2021)
Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Region (2022-2027)
Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share Forecast by Region (2022-2027)
Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) of Key Companies (2016-2021)
Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Company (2016-2021)
Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Company (2016-2021)
Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Company (2016-2021)
Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor as of 2020)
Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) of Key Company (2016-2021)
Table 18. Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Sites and Area Served
Table 19. Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2016-2021)
Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2016-2021)
Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2016-2021)
Table 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2022-2027)
Table 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2022-2027)
Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2022-2027)
Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2016-2021)
Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2016-2021)
Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2016-2021)
Table 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2022-2027)
Table 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2022-2027)
Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2022-2027)
Table 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2022-2027)
Table 38. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 39. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 40. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 42. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 43. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 44. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 45. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 46. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 47. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 48. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 49. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 50. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 51. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 52. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 54. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 55. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 56. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 57. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 58. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 59. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 60. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 61. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 62. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 63. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 64. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 65. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 66. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 67. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 68. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 69. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 70. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 71. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 72. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 73. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 74. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 75. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 76. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 78. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 79. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 80. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 81. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 82. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 83. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 84. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 85. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 98. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Company (2016-2021)
Table 99. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2016-2021)
Table 100. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2016-2021) & (US$ Million)
Table 101. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2016-2021)
Table 102. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2016-2021) & (K Units)
Table 103. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2016-2021)
Table 104. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2022-2027) & (K Units)
Table 105. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2022-2027)
Table 106. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2016-2021) & (K Units)
Table 107. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2016-2021)
Table 108. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2022-2027) & (K Units)
Table 109. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2022-2027)
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 114. AstraZeneca Recent Development
Table 115. Tesaro Corporation Information
Table 116. Tesaro Description and Business Overview
Table 117. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 119. Tesaro Recent Development
Table 120. Merck & Co Corporation Information
Table 121. Merck & Co Description and Business Overview
Table 122. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 124. Merck & Co Recent Development
Table 125. Clovis Oncology Corporation Information
Table 126. Clovis Oncology Description and Business Overview
Table 127. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 129. Clovis Oncology Recent Development
Table 130. Pfizer Corporation Information
Table 131. Pfizer Description and Business Overview
Table 132. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
Table 134. Pfizer Recent Development
Table 135. Production Base and Market Concentration Rate of Raw Material
Table 136. Key Suppliers of Raw Materials
Table 137. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Table 138. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
Table 139. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
Table 140. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
Table 141. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
Table 142. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Picture
Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2021 & 2027
Figure 6. Ovarian Cancer Examples
Figure 7. Breast Cancer Examples
Figure 8. Other Examples
Figure 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2016-2027) & (US$ Million)
Figure 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) Growth Rate (2016-2027)
Figure 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price Trends Growth Rate (2016-2027) (USD/Unit)
Figure 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region: 2016 VS 2021
Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region: 2021 VS 2027
Figure 15. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 16. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) Growth Rate (2016-2027)
Figure 17. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Million USD) Growth Rate (2016-2027)
Figure 19. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Million USD) and Growth Rate (2016-2027)
Figure 21. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Million USD) Growth Rate (2016-2027)
Figure 25. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Global 5 Largest PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor: 2016 & 2020
Figure 28. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2016-2021)
Figure 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate by Type in 2016 & 2020
Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2016-2021)
Figure 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate by Application in 2016 & 2020
Figure 33. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 34. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 35. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 36. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 37. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 38. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 39. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 40. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 41. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 42. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 43. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2020
Figure 44. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application in 2020
Figure 45. Key Raw Materials Price Trend
Figure 46. Manufacturing Cost Structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 47. Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 48. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

Global Enzyme Poly ADP Ribose Polymerase (PARP) Inhibitor Market Size, Status and Forecast 2021-2027
QFJ1-4191 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、酵素ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ニラパリブ（ゼジュラ）、オラパリブ（リンパルザ）、ルカパリブ（ルブラカ）、タラゾパリブ（タルゼンナ）...

PARP（ポリADPリボースポリメラーゼ）阻害剤のグローバル市場：規模・現状・予測2019-2025

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Status and Forecast 2019-2025
QYR9NV18254 2019年11月18日 92Pages
※当調査レポートでは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場について調査・分析し、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（...

PARP（ポリADPリボースポリメラーゼ）阻害剤のグローバル市場：規模・現状・予測2019-2025

世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場規模・現状・予測（2021年-2027年）

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Status and Forecast 2021-2027
QFJ1-5932 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（オラパリブ、タラゾパリブ）、用途別市場規模（卵巣がん、乳がん、その他）、主要地域別市場規模（北米、アメリ...

世界の酵素ポリADPリボースポリメラーゼ阻害剤市場規模・現状・予測（2021年-2027年）

Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market Size, Status and Forecast 2021-2027
QFJ1-4192 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、酵素ポリADPリボースポリメラーゼ阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ニラパリブ（ゼジュラ）、オラパリブ（リンパルザ）、ルカパリブ（ルブラカ）、タラゾパリブ（タルゼンナ））、用途別市...

世界のポリメラーゼ連鎖反応用消耗品市場規模・現状・予測（2021年-2027年）

Global Polymerase Chain Reaction Consumable Market Size, Status and Forecast 2021-2027
QFJ1-5310 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、ポリメラーゼ連鎖反応用消耗品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（PCRチューブ、PCRマイクロプレート、キャップ/蓋、その他）、用途別市場規模（研究所、臨床診断研究所、病院、製薬・バイオテ...

世界のポリメラーゼ連鎖反応（PCR）検査市場規模・現状・予測（2021年-2027年）

Global Polymerase Chain Reaction (PCR) Test Market Size, Status and Forecast 2021-2027
QFJ1-5959 2021年6月 123Pages
QYResearch社発行の本調査レポートでは、ポリメラーゼ連鎖反応（PCR）検査の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（機器、試薬・消耗品、ソフトウェア・サービス）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、ア...

世界の上皮成長因子受容体（EGFR）阻害剤市場規模・現状・予測（2021年-2027年）

Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size, Status and Forecast 2021-2027
QFJ1-5726 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、上皮成長因子受容体（EGFR）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（肺がん、大腸がん、乳がん、その他）、用途別市場規模（病院、研究所、研究機関、診療所、その他）、主要地域別市場規模（北...

世界のシクロオキシゲナーゼ2阻害剤市場規模・現状・予測（2021年-2027年）

Global Cyclooxygenase 2 Inhibitor Market Size, Status and Forecast 2021-2027
QFJ1-4086 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、シクロオキシゲナーゼ2阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（選択的コックス2阻害剤、非選択的コックス2阻害剤）、用途別市場規模（病院、専門診療所、その他）、主要地域別市場規模（北米、ア...

世界のVEGF阻害薬市場規模・現状・予測（2021年-2027年）

Global VEGF Inhibitor Drugs Market Size, Status and Forecast 2021-2027
QFJ1-6064 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、VEGF阻害薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（チロシンキナーゼ阻害剤、モノクローナル抗体、その他）、用途別市場規模（腫瘍内科、眼科、その他）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の酵素ポリADPリボースポリメラーゼ（PARP）阻害剤市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Enzyme Poly ADP Ribose Polymerase (PARP) Inhibitor Market The global Enzyme Poly ADP Ribose Polymerase (PARP) Inhibitor market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standar…
世界のPARP（ポリADPリボースポリメラーゼ）阻害剤市場規模・現状・予測（2021年-2027年） PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoti…
PARP（ポリADPリボースポリメラーゼ）阻害剤のグローバル市場：規模・現状・予測2019-2025 PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoti…
PARP（ポリADPリボースポリメラーゼ）阻害剤のグローバル市場：規模・現状・予測2019-2025 PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoti…
世界の酵素ポリADPリボースポリメラーゼ阻害剤市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market The global Enzyme Poly ADP Ribose Polymerase Inhibitor market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in …